focus -WSS

focus

author：hotspot 2025-09-30 05:03:46 - browse：5297

Vials and packaging for Leqembi, a new Alzheimer's medication approved in the U.S., but not yet in Europe. Illustration: Alex Hogan/STAT; Photo: Eisai via AP

LONDON — Starting Sunday, Alzheimer’s specialists will gather for a major conference in Amsterdam, convening at a time when the field, depending on which expert you ask, has some rare momentum behind it, with new therapies starting to show benefits for patients.

But despite the hard-won victories, the arrival of the new therapies presents a new set of challenges in Europe as countries plan for their possible rollouts, scientists and doctors told STAT.

Health systems will have to adapt to diagnose people earlier and monitor them for side effects associated with the treatments. If their medicines win European approval, companies will have to strike reimbursement deals in all member states, a process that often leaves some countries waiting years for new drugs to become available. The hurdles mean the therapies will likely be offered only at certain centers initially, constraining how many patients have access to them, doctors from across Europe said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Stop the failed accountable care organization experiment

WSS

I was wrong about Geron's blood cancer drug. Now, is it a takeover target?

Artificial intelligence use in health care faces greater scrutiny in 2024

Congress might make insulin pumps more accessible to the blind

Future doctors should be trained to promote social change

Ebola vaccine can save some who are already sick, per new study

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

focus

entertainment

Drug repurposing or repositioning? The language matters

U.K. researchers warn about biases in medical devices, algorithms

Sports medicine is finally prioritizing gender equality

Why don't Americans have at

Activists slam private health insurers over coverage restrictions

Juul documents reveal insider tactics on political lobbying

Bright Health sells Medicare Advantage business to Molina

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

United colonoscopy coverage change 'may cost lives,' doctors say

App could help diagnose ear infections more accurately — and at home

leisure time

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

CVS Caremark has created a new ploy: the drug ‘rebate credit’

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Nurses recount patients attacks

Congress must protect the remaining independent doctors

knowledge

leisure time

Wikipedia

hotspot